Rucaparib

Drug Profile

Rucaparib

Alternative Names: AG 014699; AG-14699; CO-338; PF-01367338; PF-1367338; RUBRACA; Rucaparib camsylate

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Cancer Research UK; Clovis Oncology; UNICANCER
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Breast cancer; Pancreatic cancer; Prostate cancer
  • Phase I Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Launched for Ovarian cancer (Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) - First global launch
  • 20 Dec 2016 Registered for Ovarian cancer (Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) - First global approval
  • 19 Dec 2016 Updated safety and efficacy data from a pooled analysis of the phase II ARIEL 2 and phase I/II study 10 trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater) released by Clovis Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top